O Horn-Lohrens

Suggest Changes
Learn More
The lymphocyte activation marker CD30 has been shown to be an excellent target for the immunotherapy of human Hodgkin's lymphoma. In order to develop new potent immunotoxins (ITs) against CD30, we(More)
  • 1